News coverage about Medifast (NYSE:MED) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medifast earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned press coverage about the specialty retailer an impact score of 46.0086662992845 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities analysts have recently commented on MED shares. DA Davidson raised their price objective on shares of Medifast from $65.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Sidoti reiterated a “neutral” rating and set a $55.00 target price (up previously from $49.00) on shares of Medifast in a research report on Thursday, September 21st. Finally, BidaskClub upgraded shares of Medifast from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th.
Shares of Medifast (NYSE MED) traded down $0.35 during trading hours on Friday, hitting $61.50. 77,331 shares of the stock traded hands, compared to its average volume of 89,604. The company has a market cap of $733.70, a price-to-earnings ratio of 30.90, a PEG ratio of 1.93 and a beta of 0.45.
Medifast (NYSE:MED) last released its quarterly earnings data on Tuesday, August 8th. The specialty retailer reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.10. Medifast had a net margin of 8.62% and a return on equity of 24.25%. The business had revenue of $75.70 million for the quarter, compared to analyst estimates of $71.96 million. During the same quarter last year, the firm earned $0.63 EPS. Medifast’s quarterly revenue was up 6.5% compared to the same quarter last year. sell-side analysts anticipate that Medifast will post 2.12 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 9th. Investors of record on Friday, September 22nd will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 2.08%. The ex-dividend date is Thursday, September 21st. Medifast’s payout ratio is 64.32%.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/11/05/medifast-med-receiving-somewhat-positive-news-coverage-report-finds.html.
Medifast Company Profile
Medifast, Inc is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins.
What are top analysts saying about Medifast Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Medifast Inc and related companies.